Table 1.
Socio-Demographic and Clinical Characteristics of Patients (Baseline)a
| Women | Men | Statistics | |
|---|---|---|---|
| No. of patients | 42 | 34 | |
| Age (y) (mean ± SD) | 47.95 ± 12.24 | 47.41 ± 12.99 | t = 0.18, P = .85, d = 0.04 |
| Duration of illness (y) (mean ± SD) | 12.4 ± 12.6 | 16.2 ± 12.3 | t = 1.72, P = .09, d = 0.38 |
| Place of birth | |||
| Africa | 2 (5%) | 4 (12%) | |
| North America | 28 (65%) | 21 (62%) | |
| Central or South America | 2 (5%) | 1 (3%) | Χ² = 20.32, P = .31 |
| Asia | 4 (10%) | 3 (9%) | |
| Europe | 6 (15%) | 5 (15%) | |
| No. of past suicide attempts (mean ± SD) | 0.67 ± 1.28 | 0.18 ± 0.46 | t = 2.30, P = .03, d = 0.50 |
| No. of past hospitalizations (mean ± SD) | 1.76 ± 1.45 | 1.23 ± 0.93 | t = 4.20, P = .18, d = 0.50 |
| No. of past medications (mean ± SD) | 5.21 ± 3.19 | 4.41 ± 2.01 | t = 1.28, P = .21, d = 0.30 |
| MSM (mean ± SD) | 9.92 ± 1.89 | 9.47 ± 1.67 | t = 1.33, P = .19, d = 0.25 |
| Depression severity (mean ± SD) | |||
| HAMD-17 | 24.98 ± 5.91 | 22.47 ± 5.99 | t = 1.82, P = .07, d = 0.42 |
| MADRS | 33.19 ± 9.00 | 29.79 ± 7.84 | t = 1.75, P = .08, d = 0.40 |
| QIDS-C16 | 15.71 ± 3.36 | 14.21 ± 3.81 | t = 1.80, P = .07, d = 0.42 |
| CGI-S | 5.38 ± 1.08 | 4.88 ± 1.15 | t = 1.93, P = .06, d = 0.45 |
| Comorbidities | |||
| Patients with anxiety disorders | 26 (62%) | 21 (62%) | Χ² = 0, P = 1.00 |
| Patients with substance-use disorders | 7 (17%) | 7 (21%) | Χ² = 0.2, P = .89 |
| Pharmacological strategy | |||
| AD+AP | 20 (48%) | 15 (44%) | Χ² = 0.09, P = .95 |
| AD+MS | 9 (21%) | 8 (24%) | |
| AD+AP+MS | 13 (31%) | 11 (46%) | |
| Psychotherapy | 21 (50%) | 11 (46%) | Χ² = 1.73, P = .18 |
a Abbreviations: AD, antidepressants; AP, antipsychotics; CGI-S, Clinical Global Impression rating scale; HAMD-17, 17-item Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; MS, mood stabilizers; MSM, Maudsley Staging Method; QIDS-C16, Quick Inventory of Depressive Symptomatology (Clinician-Rated); TRD, treatment-resistant depression.